BioSpace News Archive

Aerin Medical Inc. announced that the Centers for Medicare and Medicaid Services assigned payment for a new Category I Current Procedural Terminology code for endoscopic destruction of the posterior nasal nerve using radiofrequency ablation.

Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel mechanism of action, announced the presentation of new preclinical data for N17350 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held virtually and at the San Diego Convention Center from November 1-5, 2023.

Sonata Therapeutics, Inc., a biotechnology company developing a new class of therapeutics called Network Medicines™, will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had “high-risk” TA-TMA.

Theralink Technologies, Inc. announced that their long-standing, strategic partnership with the Inova Schar Cancer Institute is beginning to deliver promising results by way of assessing the feasibility and impact of the actionable information provided by the Theralink assay into Inova’s Molecular Tumor Board -based treatment decisioning making for cancer patients.

Institute of Biomedical Research Corp. is pleased to provide the following update.

In October, the Services PMI® registered 51.8 percent, 1.8 percentage points lower than September reading of 53.6 percent.

Sonoma Pharmaceuticals, Inc. announced the U.S. launch of its intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.

CVRx, Inc. announced that Centers for Medicare and Medicaid Services has reassigned the Barostim implant procedure for procedures performed in the outpatient setting as part of the 2024 Medicare Hospital Outpatient Prospective Payment System final rule.